- CEO
- Karl Gradon
- Full Time Employees
- 400
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 23 Wilson Road South Te Puke New Zealand 3153
- IPO Date
- Sep 23, 2009
- Business
- Comvita Limited Comvita Limited (NZX:CVT) manufactures and markets natural health products derived from bee products and other natural ingredients, with a focus on Mānuka honey as its core offering. The company provides a range of products including Mānuka honey in various grades such as UMF-certified variants, propolis, olive leaf extracts, Medihoney wound care solutions, elixirs, lozenges, oral care items, kids' health supplements, bee pollen, cider vinegar, skincare products, and bundles or bulk packs; it operates across categories of healthcare, personal care, wound care, and functional foods. Founded in 1974 and headquartered in Te Puke, Bay of Plenty, New Zealand, Comvita conducts global operations in over 18 countries including Australia, China, Hong Kong, Japan, South Korea, the United Kingdom, the United States, North America, Southeast Asia, and Europe, supported by more than 550 employees, its own accredited laboratory for quality testing, and sustainable practices like native tree planting and B Corp certification achieved in 2023. Recent developments include the acquisition of HoneyWorld Singapore in 2023 for NZ$10.4 million to strengthen its Asian market presence and achieve category leadership in Mānuka honey there; a failed takeover bid in November 2025 by Florenz, a subsidiary of Mark Stewart's Masthead Limited, valued at $56.4 million, prompting an ongoing recapitalisation process with banking partners; key leadership appointments in November 2025 such as permanent Chief Financial Officer Mandy Tomkins-Dancey, Chief Operating Officer Ben Duncan, and Chief People and Culture Officer Nikki Leske to support its financial reset; and new product launches in digestive health, eyecare, immunity, seasonal gifting, and higher UMF Mānuka honey ranges to diversify offerings amid inventory reduction to below $85 million and a projected return to profitability in FY26 with revenue of $212.6 million.